Clinical proteomics for diagnosis and typing of systemic amyloidoses

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 136-143

  Brambilla, Francesca ^a   Lavatelli, Francesca ^b   Merlini, Giampaolo ^b,c   Mauri, Pierluigi ^a  

^a CNR   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloidosis typing; Clinical proteomics; Laser microdissection (LMD); MudPIT; Quantitative analysis

Indexed keywords

AMYLOID PROTEIN;

AMYLOIDOSIS; ANALYTIC METHOD; CLINICAL EVALUATION; GENE MUTATION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN STRUCTURE; PROTEOMICS; REVIEW;

AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84872788378     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200097     Document Type: Review

References (61)

1. Merlini, G., Bellotti, V., Molecular mechanisms of amyloidosis. N. Engl. J. Med. 2003, 349, 583-596.
2. Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S. et al., Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17, 101-104.
3. Bergstrom, J., Murphy, C., Eulitz, M., Weiss, D. T. et al., Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem. Biophys. Res. Commun. 2001, 285, 903-908.
4. Elimova, E., Kisilevsky, R., Szarek, W. A., Ancsin, J. B., Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J. 2004, 18, 1749-1751.
5. Pepys, M. B., Rademacher, T. W., Amatayakul-Chantler, S., Williams, P. et al., Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA 1994, 91, 5602-5606.
6. Kisilevsky, R., The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status. Amyloid 2000, 130, 99-108.
7. Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A. et al., Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N. Engl. J. Med. 2002, 346, 1786-1791.
8. Comenzo, R. L., Zhou, P., Fleisher, M., Clark, B. et al., Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006, 107, 3489-3491.
9. Arbustini, E., Verga, L., Concardi, M., Palladini, G. et al., Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002, 9, 108-114.
10. Strege, R. J., Saeger, W., Linke, R. P., Diagnosis and immunohistochemical classification of systemic amyloidoses: report of 43 cases in an unselected autopsy series. Virchows Arch. 1998, 433, 19-27.
11. Solomon, A., Murphy, C. L., Westermark, P., Unreliability of immunohistochemistry for typing amyloid deposits. Arch. Pathol. Lab. Med. 2008, 132, 14-15.
12. Nepomuceno, A. I., Mason, C. J., Muddiman, D. C., Bergen, H. R. 3rd et al., Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization Fourier transform ion-cyclotron-resonance mass spectrometry. Clin. Chem. 2004, 50, 1535-1543.
13. Bergquist, J., Andersen, O., Westman, A., Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2000, 46, 1293-1300.
14. Lavatelli, F., Brambilla, F., Valentini, V., Rognoni, P. et al., A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim. Biophys. Acta 2011, 1814, 409-419.
15. Tachibana, N., Tokuda, T., Yoshida K. et al., Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid 1999, 6, 282-288.
16. Theberge, R., Connors, L., Skinner, M., Skare, J. et al., Characterization of transthyretin mutants from serum using immunoprecipitation, HPLC/electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry. Anal. Chem. 1999, 6, 54-58.
17. Theberge, R., Connors, L. H., Skinner, M., Costello, C. E., Detection of transthyretin variants using immunoprecipitation and matrix-assisted laser desorption/ionization bioreactive probes: a clinical application of mass spectrometry. J. Am. Soc. Mass Spectrom. 2000, 11, 172-175.
18. Lim, A., Prokaeva, T., McComb, M. E., Connors, L. H. et al., Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci. 2003, 12, 1775-1785.
19. Bergen, H. R. 3rd, Zeldenrust, S. R., Naylor, S., An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid 2003, 10, 190-197.
20. Bergen, H. R. 3rd, Zeldenrust, S. R., Butz, M. L., Snow, D. S. et al., Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin. Chem. 2004, 50, 1544-1552.
21. Heegaard, N. H., Hansen, M. Z., Sen, J. W., Christiansen, M. et al., Immunoaffinity chromatographic and immunoprecipitation methods combined with mass spectrometry for characterization of circulating transthyretin. J. Sep. Sci. 2006, 29, 371-377.
22. Theberge, R., Infusini, G., Tong, W., McComb, M. E. et al., Top-down analysis of small plasma proteins using an LTQ-orbitrap. Potential for mass spectrometry-based clinical assays for transthyretin and hemoglobin. Int. J. Mass Spectrom. 2011, 300, 130-142.
23. Ueda, M., Misumi, Y., Mizuguchi, M., Nakamura, M. et al., SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin. Chem. 2009, 55, 1223-1227.
24. Bergen, H. R. 3rd, Abraham, R. S., Johnson, K. L., Bradwell, A. R. et al., Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. Biomed. Chromatogr. 2004, 18, 191-201.
25. Westermark, P., Benson, L., Juul, J., Sletten, K., Use of subcutaneous abdominal fat biopsy specimen for detailed typing of amyloid fibril protein-AL by amino acid sequence analysis. J. Clin. Pathol. 1989, 42, 817-819.
26. Kaplan, B., German, G., Ravid, M., Pras, M., Determination of amyloid type by ELISA using milligram amounts of tissue. Clin. Chim. Acta 1994, 229, 171-179.
27. Murphy, C. L., Wang, S., Williams, T., Weiss, D. T. et al., Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006, 412, 48-62.
28. Vilhjalmsson, D. T., Ingolfsdottir, I. E., Thormodsson, F. R., Isolation of amyloid by solubilization in water. Methods Mol. Biol. 2012, 849, 403-410.
29. Westermark, P., Westermark, G. T., Purification of transthyretin and transthyretin fragments from amyloid-rich human tissues. Methods Mol. Biol. 2005, 299, 255-260.
30. Westermark, G. T., Westermark, P., Purification of amyloid protein AA subspecies from amyloid-rich human tissues. Methods Mol. Biol. 2005, 299, 243-254.
31. Kaplan, B., Murphy, C. L., Ratner, V., Pras, M. et al., Micro-method to isolate and purify amyloid proteins for chemical characterization. Amyloid 2001, 8, 22-29.
32. Stoppini, M., Obici, L., Lavatelli, F., Giorgetti, S. et al., Proteomics in protein misfolding diseases. Clin. Chem. Lab. Med. 2009, 47, 627-635.
33. Schönland, S. O., Hegenbart, U., Bochtler, T., Mangatter, A et al., Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012, 119, 488-493.
34. Kebbel, A., Rocken, C., Immunohistochemical classification of amyloid in surgical pathology revisited. Am. J. Surg. Pathol. 2006, 30, 673-683.
35. Linke, R. P., Oos, R., Wiegel, N. M., Nathrath, W. B., Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem. 2006, 108, 197-208.
36. Linke, R. P., Severe problems in diagnosing amyloid diseases. Acta Histochem. 2003, 105, 373-375.
37. Picken, M. M., New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr. Opin. Nephrol. Hypertens. 2007, 16, 196-203.
38. Davern, S., Tang, L. X., Williams, T. K., Macy, S. D. et al., Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am. J. Clin. Pathol. 2008, 130, 702-711.
39. Roken, C., Schwotzer, E. B., Linke, R. P., Saeger, W., The classification of amyloid deposits in clinicopathological practice. Histopathology 1996, 29, 325-335.
40. Lavatelli, F., Valentini, V., Palladini, G., Verga, L. et al., Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid 2011, 18, 59-61.
41. Seldin, D. C., Sanchorawala, V., Amyloidomics comes of age. Blood 2012, 119, 1795-1796.
42. Lavatelli, F., Perlman, D. H., Spencer, B., Prokaeva, T. et al., Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol. Cell. Proteomics 2008, 7, 1570-1583.
43. Vrana, J. A., Gamez, J. D., Madden, B. J., Theis, J. D. et al., Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009, 114, 4957-4959.
44. Brambilla, F., Lavatelli, F., Di Silvestre, D., Valentini, V. et al., Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012, 119, 1844-1847.
45. Valentini, V., Lavatelli, F., Obici, L., Donadei, S. et al., Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid 2001, 18, 56-58.
46. Murphy, C. L., Wang, S., Williams, T., Weiss, D. T. et al., Characterization of systemic amyloid deposits by mass spectrometry. Methods Enzymol. 2006, 412, 48-62.
47. Klein, C. J., Vrana, J. A., Theis, J. D., Dyck, P. J. et al., Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch. Neurol. 2011, 68, 195-199.
48. Rowczenio, D., Dogan, A., Theis, J. D., Vrana, J. A., et al., Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein a-I. Am. J. Pathol. 2011, 179, 1978-1987.
49. Sethi, S., Theis, J. D., Leung, N., Dispenzieri, A. et al., Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin. J. Am. Soc. Nephrol. 2010, 5, 2180-2187.
50. Holanda, D. G., Acharya, V. K., Dogan, A., Racusen, L. C. et al., Atypical presentation of atypical amyloid. Nephrol. Dial. Transplant. 2011, 26, 373-376.
51. Murphy, C. L., Wang, S., Kestler, D., Larsen, C., Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am. J. Kidney Dis. 2010, 56, 1100-1107.
52. Dogan, A., Vrana, J. A., Theis, J. D., Gamez, J. D. et al., Mass spectrometry-based proteomic analysis of iatrogenic insulin-mediated amyloidosis (AIns). Amyloid 2010, 17, (Suppl 1):114.
53. Lacy, M. Q., Theis, J. D., Vrana, J. A., Madan, S. et al., Lysozyme amyloidosis (ALys) affecting a family with a new variant of lysozyme gene (LYX) and hereditary haemorrhagic telangiectasia. Amyloid 2010, 17, (Suppl 1):125.
54. Sethi, S., Theis, J. D., Shiller, S. M., Nast, C. C. et al., Medullary amyloidosis associated with Apo lipoprotein A-IV deposition. Kidney Int. 2012, 81, 201-206.
55. Mauri, P., Scigelova, M., Multidimensional protein identification technology for clinical proteomic analysis. Clin. Chem. Lab. Med. 2009, 47, 636-646.
56. Washburn, M. P., Wolters, D., Yates, J. R. 3rd., Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19, 242-247.
57. Comunian, C., Rusconi, F., De Palma, A., Brunetti, P. et al., Comparative MudPIT analysis identifies different expression profiles in heart compartments. Proteomics 2011, 11, 2320-2328.
58. Simioniuc, A., Campan, M., Lionetti, V., Marinelli, M. et al., Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. Cardiovasc. Res. 2011, 90, 546-556.
59. De Palma, A., Roveri, A., Zaccarin, M., Benazzi, L. et al., Extraction methods of red blood cell membrane proteins for Multidimensional Protein Identification Technology (MudPIT) analysis. J. Chromatogr. A 2010, 1217, 5328-5336.
60. Naidoo, K., Jones, R., Dmitrovic, B., Wijesuriya et al., Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases. J. Pathol. 2012, 226, 756-763.
61. Brambilla, F., Lavatelli, F., Valentini, V., Di Silvestre, D. et al., Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid 2012, 19, 11-13.